women as pts - menopause

Question 1

menopause is associated with:

Answer 1

a marked decrease in ovarian estrogen production, resulting in low serum estradiol concentrations and vasomotor symptoms (VMS) in most women

Question 2

In postmenopausal women with no prior fragility fractures or with moderate fracture risk appropriate first-line options:

Answer 2

o alendronate (Binosto)
o risedronate (Actonel)
o zoledronic acid (Reclast)
o denosumab (Prolia, Amgen)

Question 3

in postmenopausal women w/ prior fragility fractures or high fracture risk first line options are:

Answer 3

o denosumab (Prolia)
o teriparatide (Forteo, Lilly)
o zoledronic acid (Reclast)

Question 4

MHT therapies are considered safe and effective in:

Answer 4

• Low-risk women without underlying coronary heart disease or a hx of breast cancer
• Aged less than 60
• And less than 10 years from menopause onset